RMD: RESMED INC - Commentary - Zacks Investment Research

ESTIMATES
Detailed Estimates

50.07

                        Resmed Inc: (NYSE: RMD)
                    
                                    $49.98
                                
                                    -0.09 (-0.18%)
                                
                                    Volume 428,836
                                
                                    May 20 04:03 PM ET
                                
Zacks Rank: 3-Hold  

#3
 
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                    Zacks Rank
                                                                    Definition
                                                                    Annualized Return
                                                                
                                                                    #1
                                                                    Strong Buy
                                                                    26.6%
                                                                
                                                                    #2
                                                                    Buy
                                                                    18.71%
                                                                
                                                                    #3
                                                                    Hold
                                                                    10.12%
                                                                
                                                                    #4
                                                                    Sell
                                                                    4.32%
                                                                
                                                                    #5
                                                                    Strong Sell
                                                                    2.16%
                                                                
                                                                    S&P
                                                                    500
                                                                    9.93%
                                                                
                                                        Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
Zacks Commentary

                            Get Zacks Commentary for:
                            
            Zacks Commentary For RMD
        
Apr 29, 2013 Zacks Blog: ResMed's Earnings Beat; Revs Lag
Apr 02, 2013 Zacks Blog: ResMed Protects Patent Landscape
Feb 22, 2013 Zacks Blog: Another Study for STJ's EnligHTN
Feb 22, 2013 Zacks Blog: Safeway Ticks Higher on 4Q Results
Feb 22, 2013 Zacks Blog: Symmetry Misses but Up Y-Y
Feb 20, 2013 Zacks Blog: Align Upgraded to Neutral
Feb 20, 2013 Zacks Blog: BioScrip Reaffirmed at Neutral
Feb 15, 2013 Zacks Blog: Qiagen in Collaboration with Lilly
Feb 15, 2013 Zacks Blog: Zimmer Stays at Neutral
Feb 14, 2013 Zacks Blog: The Zacks Analyst Blog Highlights: Cisco Systems, CVS Caremark, ResMed, Medical Action and MedAssets
Feb 13, 2013 Zacks Blog: Thermo Fisher Remains at Neutral
Feb 13, 2013 Zacks Blog: CVS Broadens Pharmacy Advisor

<a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="728" height="90" border="0" alt="" /></a>                

                            Quick Links
                        
Services

                                            Premium Services
Zacks Rank
Personal Finance
Commentary
Education

                                        
My Account

                                            Manage Account
Update Profile
Subscriptions
Preferences
Login/Password Help
Upgrade to Premium

                                        
Resources

                                            Help
FAQs
Disclosure
Privacy Policy
Performance
Site Map

                                        
Client Support

                                            Contact Us
Share Feedback
About Zacks
Careers
Advertise
Media

                                        
Follow Us
Facebook
Twitter
Linkedin
RSS
You Tube
Zacks Research is Reported On:

                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                        
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.